<?xml version="1.0" encoding="UTF-8"?>
<ref id="B22-viruses-12-01041">
 <label>22.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Chan</surname>
    <given-names>J.F.</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Chu</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Yuan</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Chik</surname>
    <given-names>K.K.-H.</given-names>
   </name>
   <name>
    <surname>Chan</surname>
    <given-names>C.C.-S.</given-names>
   </name>
   <name>
    <surname>Poon</surname>
    <given-names>V.K.-M.</given-names>
   </name>
   <name>
    <surname>Yip</surname>
    <given-names>C.C.-Y.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Tsang</surname>
    <given-names>J.O.-L.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy</article-title>
  <source>Antivir. Res.</source>
  <year>2018</year>
  <volume>160</volume>
  <fpage>38</fpage>
  <lpage>47</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.10.007</pub-id>
  <?supplied-pmid 30326204?>
  <pub-id pub-id-type="pmid">30326204</pub-id>
 </element-citation>
</ref>
